Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1846 to 1860 of 2208 results for guidelines

  1. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    studies available that compared the types of surgery when it published its guideline and found that: : It isn't possible to say for sure...

  2. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

  3. KardiaMobile for detecting atrial fibrillation (HTG606)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

  4. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

  5. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

  6. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

  7. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma (TA1113)

    Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.

  8. NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36)

    This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website

  9. ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions (MIB295)

    NICE has developed a medtech innovation briefing (MIB) on ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions .

  10. CentriMag for heart failure (MIB92)

    NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .

  11. The Insides System for managing intestinal failure (MIB286)

    NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .

  12. Proov Confirm for ovulation confirmation (MIB322)

    NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .

  13. Prioritising our guidance topics

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  14. Regorafenib for previously treated metastatic colorectal cancer (TA866)

    Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.

  15. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

    Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.